Médecins Sans Frontières

Protestors demand Cepheid halve the price of GeneXpert TB tests to US$5

The high cost of GeneXpert tests for TB leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

Read More →

TB activists disrupt opening of The Union Conference to protest drug corporations keeping life-saving medicines from people

Newer medicines for drug-resistant TB are desperately needed, but barriers to access, including high prices, keep them out of reach for most people around the world. 

Read More →

Price announced for new lifesaving TB drug pretomanid still too high

Pretomanid is just one part of a regimen of multiple drugs that people need. MSF has been calling for the price of a complete DR-TB treatment course to be no higher than $500 per person.

Read More →

Global campaign launched urging Johnson & Johnson to reduce price of bedaquiline

Médecins Sans Frontières launches a global campaign calling on Johnson & Johnson to lower the price of bedaquiline to no more than US$1 per day.

Read More →

TB drug delamanid must be more affordable and made available in more countries

Médecins Sans Frontières acknowledges the lower price offered to the government of South Africa for delamanid, but calls for it to be significantly lower and expanded to all countries in need.

Read More →

MSF technical brief: Making the switch

Saving more lives with optimal treatment for drug-resistant TB.

Read More →

Vacancy: TB Advocacy Advisor

Médecins Sans Frontières (MSF) is seeking a TB Advocacy Advisor to support MSF TB advocacy through the development and implementation of national, regional and global advocacy action plans.

Read More →

Beware the Global Fund procurement cliff

Safeguarding supply of affordable quality medicines and diagnostics in context of risky transitions and co-financing.

Read More →

MSF technical brief: A rapid TB test for people living with HIV

TB LAM can help close the deadly TB testing gap.

Read More →

Crisis of confidence in the WHO's ability to produce normative guidance for the treatment of RR-/MDR-TB

Advocates request an urgent in-person meeting with the WHO leadership to discuss concrete actions to address technical and guideline development process-related issues previously raised.

Read More →

Page 1 of 7 · Total posts: 10

1 2 Last→